---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005540"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:00:16.086593+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M

## Summary
- Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.
- Revenue growth driven by Nora Pharma generic drug sales, acquired Oct 2022.
- Q2 2023 revenues up 13.6% sequentially from Q1 2023.
- CEO Dr. Steve Slilaty expressed optimism for continued growth.

## SEC filing metadata
- accession: 0001683168-23-005540
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/0001683168-23-005540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005540
- JSON: https://secwatch.observer/filing/0001683168-23-005540.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005540.txt

## Key facts
- Earnings Releases
  Sunshine Biopharma Inc. reported the 2023 second quarter results: revenue $5,560,865.
  - Period: the 2023 second quarter
  - Revenue: $5,560,865
  - Result: reported results
  source text: of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/0001683168-23-005540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.